Monash University joins Pfizer research network

Pfizer and MNHS – a strategic alliance

Pfizer’s Center of Therapeutic Innovation (CTI) decided to enter into an agreement with Monash University, based on the University’s scientific excellence, culture of innovation, and strong focus on translation of basic science into the clinic. We are delighted with the partnership and excited to help enable scientists at Monash to translate new concepts into transformational new drugs to treat diseases of high unmet medical need.

Anthony J. Coyle - Pfizer’s Center of Therapeutic Innovation

The Faculty of Medicine, Nursing and Health Sciences at Monash was the first non-USA-based entity to join Pfizer’s Centers for Therapeutic Innovation (CTI), a unique model for academic-industry collaboration, designed to bridge the gap between early scientific discovery and its translation into new medicines.

The strategic alliance between Pfizer and MNHS has been established to co-develop high value targets, currently focusing on novel therapies for cancer and fibrosis. Pfizer has benefited from the partnership by getting access to world-leading science and novel therapeutic targets while Monash has gained exposure to the industry translation process and seized opportunities to engage at a very early stage of the R&D process. Read more about Pfizer’s Centers for Therapeutic Innovation (CTI) here